Africa, Biden Admin, Biden regime, Canada, cash cow, CDC, contact tracing, Copyright, COVID-19, Democratic Republic of Congo, DRC, Ebola, Ebola contact tracing, Ebola outbreak, Ebola spread, Ebola vaccine, Europe, flu, Guinea, Illegal immigrants, immunizing, legal immigrants, Merck, mining, NewLink Genetics, Oregon, outbreak, Patent length, patents, pharmaceutical patents, quarantine, Vaccination, Vaccines, Washington State
Washington State and Oregon apparently haven’t quarantined those who have been to zones with Ebola outbreaks but seem to be just calling them up and asking how they are doing! That’s what we deduce from the little information provided in their news releases (below). Judge for yourself. It’s difficult to travel to and from Europe due to Covid-19, and yet neither the Biden Admin nor these States appear to be taking this Ebola outbreak very seriously. The Oregon news release implies that they don’t speak English!
No information is given as to why these people were traveling in an Ebola outbreak zone. Did these people come into the United States illegally across the border? Are they new Americans or legal immigrants who went back home to visit, despite Covid-19? Do they work for mining companies? Are they medical workers? They aren’t telling us. This gives a deja vu for the Covid-19 outbreaks in Washington State and Oregon last year. The first documented case of Covid was in Washington State, though they think that it may have arrived elsewhere first.
Ebola vaccine would be a cash cow for the Government of Canada, right across the border from Washington State and Oregon. And, Merck pharmaceuticals. Plus, others who may be developing vaccines.
“The discovery of the Ebola vaccine was funded by the Public Health Agency of Canada and the Canadian Safety and Security Program and required collaboration with government departments, investment by private industry and importantly, international partnerships. The intellectual property rights for the vaccine belong to the Government of Canada. It has been licensed to NewLink Genetics, and on November 24, 2014, NewLink Genetics and Merck announced their collaboration on the vaccine and they have the responsibility to produce mass quantities and to complete clinical trials for the vaccine.” Read more at the link: https://www.canada.ca/en/public-health/services/infectious-diseases/fact-sheet-ebov-canada-s-experimental-vaccine-ebola.html
They need to extend the length of time for patents and decrease the length for copyright, so that the pharmaceutical companies (and governments) have less incentive for disease spread. With a twenty year patent they need a new disease every 20 years, at least. Patent extension can be in exchange for an affordable price on patented medicines.
Vaccinating the entire population, as frequently as possible, seems to be a real cash cow for pharmaceutical companies. Changes in the flu means that people get annual shots. The same could become true of Covid-19. And, an Ebola spread would give an opportunity to sell their vaccines to everyone.
From the March 4th CDC “contact tracing” directive. Given what this says, why are only 27 being monitored? Are there more? “There are currently outbreaks of EVD in DRC and Guinea. As of February 23, 2021, there were 8 cases of EVD in DRC and 9 in Guinea. Currently, according to CBP, a daily average of 27 travelers arrive in the United States each day from DRC and 33 from Guinea. A very small number (an average of between two and six per day) are neither United States citizens nor lawful permanent residents of the United States. Over 96% of travelers arriving from these countries enter the United States at one of six U.S. airports: Washington-Dulles International Airport (IAD), Virginia; John F. Kennedy International Airport (JFK), New York; Newark Liberty International Airport (EWR), New Jersey; Chicago O’Hare International Airport (ORD), Illinois; Atlanta Hartsfield-Jackson Atlanta International Airport (ATL), Georgia; and Los Angeles International Airport (LAX), California. Experience with previous EVD outbreaks (including the 2014-2016 EVD outbreak in West Africa) shows that EVD can spread quickly between close contacts and within healthcare settings, often with high case fatality rates, and with substantial disruption and strain on healthcare services and broader socioeconomic impacts. While information continues to be gathered regarding these most recent EVD cases, there is potential for spread within the affected countries and to surrounding countries in both West Africa and Central/East Africa.
Air travel has the potential to transport people, some of whom may have been exposed to a communicable disease, anywhere across the globe in less than 24 hours. CDC considers it essential that U.S. public health authorities have access to information necessary to follow up with travelers arriving from countries with EVD outbreaks, as needed, including for health education, risk assessment, and symptom monitoring. U.S. state, local, tribal, and territorial health departments have the authority to implement and manage public health follow-up, including monitoring, conducted within their jurisdictions. Health departments may elect to assume direct responsibility for monitoring or accept monitoring by a sponsoring organization (e.g., if the individual was de-ployed overseas by a private company).2
Timely public health follow-up requires health officials to have immediate access to accurate and complete contact information for passengers as they arrive in the United States. Inaccurate or in-complete contact information hampers the ability of public health authorities to protect the health of passengers and the public. The best way to ensure airline passengers’ contact information is available in real time is to collect the information before they board a flight. CDC has identified the minimum amount of information needed to locate passengers reliably after they arrive in the United States: full name, address while in the United States, primary contact phone number, sec-ondary or emergency contact phone number, and email address.“ Despite the name of the file, this seems to be contact tracing but no quarantine. Read more here: https://www.cdc.gov/quarantine/pdf/CDC-EVD-Contact-Tracing-Order_03-02-2021_encrypted-p.pdf
From the CDC re the vaccine:
“Ebola virus is a zoonotic pathogen that causes severe hemorrhagic fever in humans, known as Ebola virus disease (EVD). There are four species of Ebola virus that have been known to cause disease in humans. Of these, species Zaire ebolavirus (EBOV) is the most lethal, with case fatality rates of 70–90% if left untreated. EBOV is responsible for the majority of recorded EVD outbreaks. This includes the two largest EVD outbreaks in history, the 2014–2016 West Africa outbreak and the 2018 outbreak in eastern Democratic Republic of the Congo, where over 32,000 people were infected, and more than 13,600 deaths were reported.
Importation of EVD to the United States from an epidemic region through an infected traveler is a recognized risk with the potential for spread to other people. During the 2014–2016 Ebola outbreak in West Africa, 11 people were treated for EVD in the U.S., and two of them died. Nine of these cases were imported into the U.S. Two were domestic healthcare workers who were infected while caring for the first travel-associated EVD case diagnosed in the U.S. Both healthcare workers recovered.
The Ebola virus vaccine*
The Ebola virus (Zaire ebolavirus) vaccine is a replication-competent, live, attenuated recombinant vesicular stomatitis virus (rVSV) vaccine. It is known as rVSVΔG-ZEBOV-GP Ebola vaccine (brand name Ervebo®) and manufactured by Merck. It is not possible to become infected with EBOV from the vaccine because the vaccine only contains a gene from the Ebola virus, not the whole virus. Specifically, it contains a gene for the EBOV glycoprotein that replaces the gene for the native VSV glycoprotein. Ervebo® does not provide protection against other species of Ebolavirus or Marburgvirus.
The vaccine was approved by the U.S. Food and Drug Administration (FDA) on December 19, 2019, for the prevention of EVD caused by EBOV in people 18 years of age and older, based on the data from 12 clinical trials that included a total of 15,399 adults.
Antibody measurements are often used as a surrogate test to predict when protection by a vaccine can be expected. Clinical trials have shown that the vaccine elicits rapid antibody response in 14 days after a single dose. Clinical efficacy of the vaccine was supported by a randomized cluster (ring) vaccination study during the 2014–2016 outbreak in Guinea. In this study, 3,775 people in close contact with diagnosed EVD cases (contacts) and their close contacts (contacts of contacts) received immediate vaccination. No one who was vaccinated immediately developed EVD 10 or more days after vaccination.
The correlate of protection, or the specific immune response to the Ervebo® vaccine that closely relates to protection against infection with EBOV, is unknown and still being studied. The duration of protection by Ervebo® against EBOV is unknown. It is also not known whether it is effective when administered concurrently with antiviral medication, immune globulin, and/or blood or plasma transfusion.
Ebola vaccine eligibility
On February 26, 2020, the Advisory Committee on Immunization Practices (ACIP) recommended pre-exposure vaccination with Ervebo® for adults aged 18 years or older in the U.S. population who are at potential risk of exposure to EBOV. This recommendation includes adults who are
1. Responding or may respond to an outbreak of EVD;
2. Laboratorians or other staff working at biosafety-level 4 facilities in the United States; or
3. Healthcare personnel* working at federally designated Ebola Treatment Centers in the United States.
*Disclaimer: The mention of any product names or non-United States Government entities on CDC Ebola websites is not meant to serve as an official endorsement of any such product or entity by the CDC, the Department of Health and Human Service, or the United States Government“. https://www.cdc.gov/vhf/ebola/clinicians/vaccine/index.html
Dr. Rasmussen is affiliated with Georgetown where Kamala’s husband is now teaching. It is a private Jesuit university: “Dr Rasmussen called for increased vaccination for those in communities affected by Ebola to prevent further outbreaks”. See: “HEALTH FEARS Ebola ‘outbreak’ possible in Washington and Oregon as 27 people who recently traveled from West Africa being monitored” by Mollie Mansfield 26 Mar 2021, 14:08 Updated: 26 Mar 2021, 21:43 https://archive.is/GkhjN Regarding Georgetown: https://en.wikipedia.org/wiki/List_of_Georgetown_University_alumni https://en.wikipedia.org/wiki/Georgetown_University The irony of it being a Jesuit school is that the whole reason that the UK had a German King George was to keep the UK non-Catholic! https://en.wikipedia.org/wiki/Georgetown_(Washington,_D.C.)
“ORDER OF THE CENTERS FOR DISEASE CONTROL AND PREVENTION, DEPARTMENT OF HEALTH AND HUMAN SERVICES,
REQUIREMENT FOR AIRLINES TO COLLECT DESIGNATED INFORMATION FOR PASSENGERS DESTINED FOR THE UNITED STATES WHO ARE DEPARTING FROM, OR WERE OTHERWISE PRESENT IN, THE DEMOCRATIC REPUBLIC OF THE CONGO OR THE REPUBLIC OF GUINEA
UNDER 42 CFR 71.4, 71.20, 71.31, AND 71.32 AS AUTHORIZED BY 42 U.S.C. 264 AND 268
• All airlines and aircraft operators conducting any passenger-carrying operation destined for the United States transporting passengers who are departing from or were otherwise present in the Democratic Republic of the Congo (DRC) or the Republic of Guinea (Guinea) within 21 days of the date of the person’s entry or attempted entry into the United States; and • All air passengers destined for the United States who are departing from or were otherwise present in the DRC or Guinea within the previous 21 days of the date of the person’s entry or attempted entry into the United States.
The Director of the Centers for Disease Control and Prevention (CDC) (Director) has issued an order (Order) under 42 CFR 71.4, 71.20, 71.31 and 71.32. This Order, as detailed below, requires all passengers destined for the United States who are departing from, or were otherwise present in, DRC or Guinea within the previous 21 days to provide designated contact information, as further described herein, to the airline or aircraft operator, so this information can be provided by the airline or aircraft operator, as required by this Order, to the United States Government. The collection of this information will begin for flights departing after 11:59 p.m. Eastern Standard Time on March 4, 2021.” Apparently merely a contact tracing order and not a quarantine order. Read more here: https://www.cdc.gov/quarantine/pdf/CDC-EVD-Contact-Tracing-Order_03-02-2021_encrypted-p.pdf
From the State of Oregon:
“Media availability: Dr. Richard Leman will be available to answer media questions today at 11 a.m. Media will be able to join by calling 844-721-7239, access code 283749.
March 25, 2021
Media Contact: OHA External Relations, PHD.Communications@dhsoha.state.or.us
OHA monitoring four people for Ebola following travel from affected countries
PORTLAND, Ore. — Public health officials in Oregon are monitoring four people who recently visited the West African countries of Guinea and Democratic Republic of the Congo (DRC). Regions in each of these countries are currently experiencing outbreaks of Ebola virus disease. There is low risk for people in Oregon.
Oregon Health Authority (OHA) and local public health departments have been in contact with these individuals, who are considered “persons under monitoring,” since they arrived in the state earlier in March. The goal of this contact is to determine their risk, if any, of being exposed to Ebola and ensure their safety, as well as the safety of their families and the community.
“We want to make sure these individuals have the support they need to monitor their health, stay in contact with public health officials and safely get help with medical services if it comes to that,” said Richard Leman, M.D., Chief Medical Officer for Health Security, Preparedness and Response at the OHA Public Health Division.
As of March 24, Guinea has reported 18 Ebola cases and nine Ebola-related deaths. The Guinea outbreak is centered in Nzérékoré Prefecture, which is in the southern region of the country near the Liberian border. Democratic Republic of the Congo has reported 12 Ebola cases and six Ebola-related deaths. The outbreak in DRC is in North Kivu Province, which is in the eastern part of the country near the Ugandan border. The outbreaks are limited to small areas of each country and are not in large population centers.
The Centers for Disease Control and Prevention (CDC) has issued Level 3 travel warnings for the affected regions in both countries, recommending people avoid nonessential travel there.
Beginning March 4, CDC has required all airlines to supply contact information for all U.S.-bound travelers who have been in Guinea or Democratic Republic of the Congo in the last 21 days — the largest known incubation period for Ebola. U.S.-bound travelers who have been in affected countries are routed through six international airports: Dulles in Washington, D.C.; John F. Kennedy in Queens, NY; Newark Liberty in Newark, NJ; O’Hare in Chicago, IL; Hartsfield-Jackson in Atlanta, GA; and LAX in Los Angeles, CA. Upon arrival, they are interviewed to determine if they are symptomatic and to confirm their contact information. If they are symptomatic, they will be offered medical evaluation.
CDC shares information for travelers from affected regions whose itineraries include Oregon. That way, public health authorities can contact these travelers and ensure they know symptoms to watch for and how to receive prompt medical evaluation if they become ill with symptoms consistent with Ebola. OHA and local public health officials also are reaching out to international non-governmental organizations with services in the affected countries to request early notification for any volunteers traveling to Oregon after recent work in those areas.
In addition, OHA and local public health officials are contacting community-based organizations in Oregon to help the persons under monitoring with language access and other support services” https://content.govdelivery.com/accounts/ORDHS/bulletins/2c95dc9
SO THOSE UNDER MONITORING DON’T SPEAK ENGLISH? ARE THEY ILLEGALS? WHY ARE THEY HERE?
DRC is Central Africa. However, a small part of it is on the west African coast.
From the State of Washington:
For immediate release: March 25, 2021 (21-083)
Media contact: DOH Communications
Public health officials monitor low-risk travelers from Ebola-affected regions
OLYMPIA — Public health officials in Washington are monitoring 23 low-risk individuals who recently traveled from the West African countries of Guinea and Democratic Republic of the Congo (DRC). Regions in each of these countries are currently experiencing outbreaks of Ebola virus disease (EVD). There is low risk for people in Washington.
Local public health officials in Washington have been in contact with these individuals, who are considered “persons under monitoring” for 21 days after their arrival to the United States.
There is an outbreak of EVD in N’Zérékoré Prefecture of Guinea and the North Kivu Province in the Democratic Republic of Congo. The Centers for Disease Control & Prevention (CDC) has issued an order requiring airlines to collect and provide CDC with contact information for passengers who were in Guinea or the Democratic Republic of Congo within the 21 days before arriving in the United States.
Once travelers from Guinea or the Democratic Republic of the Congo arrive in the United States, public health officials are notified and conduct health monitoring and other public health follow-up for 21 days after their arrival.
The risk of getting EVD in the United States is very low. EVD is a rare and deadly disease in people and nonhuman primates. The viruses that cause EVD are located mainly in sub-Saharan Africa. People can get EVD through direct contact with an infected animal (bat or nonhuman primate) or a sick or dead person infected with Ebola virus.
More information on EVD can be found on the CDC’s Ebola virus disease website.
Posted in: Health News
Actions: E-mail | Permalink
Printable Version (PDF) https://www.doh.wa.gov/Portals/1/Documents/1600/NewsReleases/2021/21-083-EbolaMonitoring-NewsRelease.pdf
Their last statement is dangerously and inanely stupid. The risk is low if we didn’t allow people to come and go from infected areas. But, the US is allowing this travel. In an airplane people share toilets, so the risk of exposure to “bodily fluids” is there. Stupid statement: “The risk of getting EVD in the United States is very low. EVD is a rare and deadly disease in people and nonhuman primates. The viruses that cause EVD are located mainly in sub-Saharan Africa. People can get EVD through direct contact with an infected animal (bat or nonhuman primate) or a sick or dead person infected with Ebola virus. And, don’t believe it when they say that people who don’t display symptoms can’t spread infectious diseases. Virus’ are about survival of the fittest and that means spreading it around to as many people as possible. The virus can spread to more people if the person isn’t showing symptoms. Of course the germ load is usually higher when the person is ill. Virus’ and bacteria are constantly evolving, which is one reason they really know little about them.